甲状腺相关眼病治疗新进展  

New progress in the treatment of thyroid-associated ophthalmopathy

作　　者：冯会 孙建平[1] 段薇[1] Feng Hui;Sun Jianping;Duan Wei(Department of Endocrinology,The Affiliated Zhongshan Hospital of Dalian University,Dalian 116001,China)

机构地区：[1]大连大学附属中山医院内分泌科,116001

出　　处：《国际内分泌代谢杂志》2020年第2期104-107,共4页International Journal of Endocrinology and Metabolism

基　　金：大连市科技创新基金项目(2019J13SN107)。

摘　　要：甲状腺相关眼病(TAO)是临床常见、发病率高的自身免疫性眼眶疾病,糖皮质激素是一线主流用药,鉴于使用者对其不良反应的忌惮以及部分患者对糖皮质激素治疗的不敏感,目前,已有诸多可改善TAO进程的药物在研发和临床应用前期中:从拮抗白细胞介素(IL)-6受体和肿瘤坏死因子(TNF)-α等免疫靶向治疗,到阻滞促甲状腺激素(TSH)受体产生甲状腺自身抗体;从拮抗胰岛素样生长因子(IGF)-1受体减少眼眶成纤维细胞活化,到锝-亚甲基二磷酸盐注射液(99Tc-MDP)、他汀类等调节自身免疫炎性反应,甚至从有效治疗Graves病的免疫疗法中也可以寻找到有望解决TAO的方法。Thyroid-associated ophthalmopathy(TAO)is an autoimmune disorder of the orbit with high incidence.Glucocorticoids are the first choice of mainstream medicine for TAO.But because of side effects and the insensitivity of glucocorticoids in patients with TAO,many new drugs improving TAO have been researched and applied in pre-clinical trial in recent years:from interleukin-6 receptor and tumor necrosis factor-αin immunotargeted therapies to blocker of thyroid stimulating hormone receptor(TSHR)production,from antagonizer of insulin-like growth factor 1 receptor reducing the activation of orbital fibroblasts to 99Tc-MDP(99Technetium-Methylenediphosphonate),statins which regulate autoimmune response.And even more,those effective immunoregulating medicine for Graves′disease are expected promising solutions to TAO.

关 键 词：甲状腺相关眼病 GRAVES眼病 自身免疫 

分 类 号：R77[医药卫生—眼科] R5[医药卫生—临床医学]